I don't think you really looked into this research.
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Many monoclonal antibodies are used to treat cancer. They are a type of targeted cancer therapy, which means they are designed to interact with specific targets.
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies
What that article is actually talking about is: Immune Checkpoint Inhibitors.
"None of the patients reported adverse reactions during the drug trial, which is rare in treatments of its type. According to The New York Times, about 20% of patients treated with checkpoint inhibitors have some sort of adverse reaction."
https://www.thegatewaypundit.com/2022/06/miracle-drug-shows-100-remission-cancer-patients-drug-trial/
Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body.
Immune checkpoints engage when proteins on the surface of immune cells called T cells recognize and bind to partner proteins on other cells, such as some tumor cells. These proteins are called immune checkpoint proteins. When the checkpoint and partner proteins bind together, they send an “off” signal to the T cells. This can prevent the immune system from destroying the cancer.
mmunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pd-l1
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ctla-4